Opthea

Fred Guerard, PharmD, CEO of Opthea, will present at the Bell Potter Healthcare Conference, November 18, 2024, and participate in the Jefferies London Healthcare Conference, November 19, 2024. For more details, please read the press release: https://lnkd.in/eASbAqAx #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

At EURETINA 2024, Professor Timothy Jackson spoke with Healio about his talk titled VEGF-A/C/D inhibition with sozinibercept and ranibizumab combination therapy for nAMD. He shared why he is excited about the Phase 2b results of sozinibercept in combination with ranibizumab showing superior visual gains over ranibizumab monotherapy. Thanks @Healio for the interview! Watch the full interview here: https://lnkd.in/ejyUcatB #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #Euretina2024

The majority of wet AMD patients fail to achieve 20/40 vision, critical to a person’s ability to drive, read and maintain other instrumental activities of daily living. Every letter counts when it comes to improving vision and living a fuller life. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

Vision loss is the number one concern among patients with blinding diseases. Not being able to perform instrumental activities of daily living like driving, reading, or cooking affects a person’s independence and quality of life. Every letter counts when it comes to improving and restoring eyesight in patients with wet AMD and other vision-threatening diseases.   #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

David Boyer, MD, will present an update on Opthea’s wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy. To read the press release: https://lnkd.in/etF6FkWN #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #InnovateRetina

Join us in celebrating World Sight Day on October 10, 2024, and spread the word about the importance of taking care of your eyes. Proper eye care is important at all ages. This year’s World Sight Day focuses on the importance of eye care in young people, and inspiring children everywhere to love their eyes. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #WorldSightDay #Loveyoureyes

Opthea today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. To read full press release: https://lnkd.in/ehXXUcYT   #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

At EURETINA 2024, Professor Timothy Jackson spoke with Modern Retina and Ophthalmology Times Europe about his talk titled “VEGF-A/C/D inhibition with sozinibercept and ranibizumab combination therapy for nAMD.” He shared why he is excited about the sozinibercept Phase 2b results showing superior visual gains over ranibizumab monotherapy. In the interview Professor Jackson said: “There's nothing else, that I'm aware of, that's setting the bar high enough to actually aim for a superior visual acuity output.” Thanks @ModernRetina for the interview! See the full interview here: https://lnkd.in/eAH4zg7N #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #Euretina2024

  Wet AMD remains the leading cause of vision loss in the elderly, impacting about 3.5 million people in the US and Europe alone. The unmet medical need in wet AMD is significant, with many patients failing to achieve optimal vision outcomes or even losing vision over time, despite treatment with anti-VEGF-A therapies. World Retina Day reminds us to take care of our eyes by getting them checked regularly, avoiding excessive smoking or drinking, and by being mindful when using electronic devices as they emit blue light harmful to retinas over time. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #WorldRetinaDay

Wet AMD is one of the most common retinal diseases, leading to vision decline caused by excess VEGF. VEGF is a protein produced by cells that stimulates the formation of abnormal new blood vessels behind the retina. The leakage of fluid and protein from the vessels causes retinal degeneration and leads to severe and rapid loss of vision. Early intervention is essential to treat wet AMD. World Retina Day reminds us to take care of our eyes by getting them checked regularly, avoiding excessive smoking or drinking, and by being mindful when using electronic devices as they emit blue light harmful to retinas over time. #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept #WorldRetinaDay